Article
Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
BMC cancer - 31 Aug 2020
Damato Angela, Iachetta Francesco, Antonuzzo Lorenzo, Nasti Guglielmo, Bergamo Francesca, Bordonaro Roberto, Maiello Evaristo, Zaniboni Alberto, Tonini Giuseppe, Romagnani Alessandra, Berselli Annalisa, Normanno Nicola, Pinto Carmine
Abstract excerpt
BACKGROUND: FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab has shown to be one of the therapeutic regimens in first line with the highest activity in patients (pts.) with metastatic colorectal cancer (mCRC) unselected for biomolecular alterations. Generally, tumors co-opt the programmed death-1/ligand 1 (PD-1/PD-L1) signaling pathway as one key mechanism to evade immune...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.